Daehwa Pharm (067080) Stock Outlook 2026: The Oral Paclitaxel Bet Behind 'Liporaxel'
A 2026 outlook on Daehwa Pharm (KRX: 067080), the Korean small-cap pharma behind Liporaxel, an oral paclitaxel formulation. Covers the commercialization path, the generic/API business that funds R&D, and the concentration risk that comes with betting on a single pipeline asset.